斯塔基德林通过激活线粒细胞吸食来缓解人类透镜上皮细胞中高葡萄糖诱导的亡
Guijia Wu1, Xiteng Chen1, Wei Wang1
1Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, China.
Experimental eye research
|August 15, 2025
概括
在糖尿病白内障 (DC) 模型中,稳素 (STA) 能防止高葡萄糖诱导的损伤. 这种天然化合物增强了自和线粒体功能,表明DC治疗的治疗潜力.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病白内障 (DC) 是糖尿病患者视力障碍的主要原因之一.
- 天然植物提取物在DC预防和治疗方面表现有前途.
- 斯塔基德林 (STA) 来自Leonurus heterophyllus Sweet,具有很高的生物利用性和很少的副作用.
研究的目的:
- 调查斯塔基德林 (STA) 对高葡萄糖诱导的透镜上皮细胞损伤的保护作用.
- 阐明潜在的机制,专注于自和线粒体完整性.
主要方法:
- 使用HLE-B3细胞建立了一个高葡萄糖细胞模型.
- 评估了细胞亡,线粒体形态 (ImageJ),自细胞形成和 lysosomal活动.
- 利用3-甲基氨酸 (3-MA) 作为一种自抑制剂来探索STA的机制.
主要成果:
- 高葡萄糖诱导了亡和线粒体损伤,同时降低了自.
- 通过增加自 (LC3B,P62) 和恢复线粒体形态,STA治疗抵消了高葡萄糖的影响.
- 使用3-MA抑制自会逆转STA对亡和线粒体的保护作用.
结论:
- 斯塔基德林 (STA) 保护透镜上皮细胞免受高葡萄糖诱导的损伤.
- STA的保护作用是通过调节自性依赖的过程 - - 线性的调节来调节的.
- 在治疗糖尿病白内障方面,STA显示出治疗潜力.
关键词:
3-MA 的使用方法.细胞亡是细胞的亡.糖尿病白内障是什么 糖尿病白内障线粒细胞衰变 (mitophagy) 是一种神经衰变的过程.斯塔基德林 (Stachydrine) 是一种稳固的化合物.更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.3K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
546
相关概念视频
01:58Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...